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Abstract
Background: Atherosclerosis is as a systemic inflammatory disease associated with the activation 
of many mediators, including matrix metalloproteinases (MMPs), and may be amplified by abnormal 
high serum uric acid (UA) concentration (hyperuricemia, HU). The aim of the study was to determine 
the relationship between serum UA concentration and activity of MMPs and their correlation with the 
hypertension-mediated organ damage (HMOD) intensity.
Methods: One hundred and nine patients untreated with antihypertensive, hypolipemic or urate-
lowering drugs with diagnosed stage 1–2 essential hypertension were included in this study. In all par-
ticipants blood pressure (BP) was measured, carotid-femoral pulse wave velocity (PWV), intima–media 
thickness (IMT),  echocardiography and blood tests including UA, lipids and serum concentrations of 
MMPs (1, 2, 3, 9) were observed. The participants were divided into hyper- and normuricemic groups.
Results: Uric acid concentration in the whole study group positively correlated with some HMOD 
parameters (IMT, PWV, left ventricular mass index, left atrial dimension). Among the studied metal-
loproteinases only MMP-3 activity positively correlated with serum UA concentration independently 
of age, body mass index and serum lipids (R2 = 0.11, p = 0.048). Multivariate regression analysis 
showed positive association between IMT and BP, UA concentration and MMP-3 activity, independently 
of waist circumference and serum lipids (R2 = 0.328, p < 0.002). Patients with HU were characterized 
by higher activity of MMP-3 than those without (19.41 [14.45; 21.74] vs. 13.98 [9.52; 18.97] ng/mL,  
p = 0.016).
Conclusions: The present results may support the thesis that UA and the increased by UA activity of 
MMPs may take part in the development of HMOD, especially IMT. (Cardiol J XXXX; XX, X: xx–xx)
Key words: arterial hypertension, uric acid, hyperuricemia, matrix metalloproteinases, 
metabolic syndrome
Introduction
Cardiovascular disorders caused by atheroscle-
rosis remain the main cause of morbidity and death 
in developed countries. Currently atherosclerosis 
is defined as a systemic inflammatory disease as-
sociated with the activation of many mediators and 
effectors, including excessive activation of matrix 
metalloproteinases (MMPs) [1] MMPs are a large 
group of zinc-dependent proteolytic enzymes which 
play a key role in physiological and pathological 
inflammatory processes, including activation of 
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immune cells, damage and apoptosis of endothe-
lial cells, fibrosis and remodeling of vascular wall. 
Increased activity of MMPs was described in many 
inflammatory diseases as well as in selected car-
diovascular diseases [2, 3]. 
Under physiological conditions MMPs are 
inhibited by a group of tissue inhibitors of metal-
loproteinases (TIMPs) [4, 5]. The collagenases 
(MMP-1, -8, -13, -18) are capable of breaking down 
interstitial collagen I, II, III. Collagen fragments 
are further degraded by gelatinases (MMP-2, -9), 
MMP-2, -9 are also involved in the degradation 
of collagen IV, vessel remodeling, angiogenesis, 
inflammation and atherosclerotic plaque rupture. 
Stromelysin-1 (MMP-3) and stromelysin-2 (MMP-
10) play the key role in extracellular matrix protein 
degradation by activation of MMPs cascade [6–8]. 
Essential hypertension is associated with vas-
cular wall remodeling, which may be amplified by 
abnormal high serum uric acid (UA) concentration 
Increased UA concentration is called hyperurice-
mia (HU). HU is a common condition which may 
affect up to a quarter of the adult population [9, 
10]. Many factors promote the development of HU, 
especially: the use of a high-purine diet, sedentary 
lifestyle, metabolic syndrome, obesity and arterial 
hypertension. In most cases, HU is accompanied by 
high estimated cardiovascular risk [11, 12]. 
Uric acid is an important antioxidant, but in 
excessive amounts it can activate the formation 
of reactive oxygen species. UA participates in 
atherogenesis process by enhancing inflammation, 
causing endothelium dysfunction, vascular smooth 
muscle proliferation, increased platelet adhesion 
and lipid peroxidation [13]. In subjects with arte-
rial hypertension HU is associated with increased 
risk of coronary heart disease and cardiovascular 
mortality [14, 15]. 
The action mechanism of elevated UA con-
centration on the progression of vascular changes 
has yet to be clearly identified. Available data in 
the literature about the relationship between HU 
and MMPs activity is limited. 
The aim of the study was to determine the 
relationship between serum UA concentration and 
selected MMPs activity and their correlation with 
hypertension-mediated organ damage (HMOD).
Methods
The study group consisted of consecutive 
patients with diagnosed essential hypertension 
stage 1 or 2 (blood pressure [BP] ≥ 140/90 and < 
180/110 mmHg) in accordance with the 2018 Euro-
pean Society of Hypertension/European Society of 
Cardiology (ESH/ESC) guidelines [16]. They were 
admitted within a 6 month period to the hyperten-
sion outpatient department. Subjects were both 
women and men aged 20–80 years. The exclusion 
criteria included: symptomatic gout, coronary 
heart disease (previous myocardial infarction, 
coronary angioplasty procedure or coronary artery 
bypass surgery), atrial fibrillation, stroke history 
or transient ischemic attack episode, active acute 
or chronic inflammatory process, cancer, kidney or 
liver failure and reported treatment with antihy-
pertensive, hypolipemic or urate-lowering drugs 
in the prior 4 weeks.
Study procedures 
 All participants underwent medical exami-
nation, with office BP measurements in standard 
conditions, after 10 min rest, in a sitting position 
on the non-dominant arm with the use of the Om-
ron M5-I oscillometric device (Omron Healthcare 
Co., Japan). The mean of the three measurements 
at 1-min intervals was taken for analysis. 24-h am-
bulatory blood pressure monitoring (ABPM) was 
also performed using a SpaceLabs 90207 recorder 
(SpaceLabs Inc, Richmond, Washington, USA) ac-
cording to ESH/ESC recommendations [16]. The 
SphygmoCor (AtCor Medical, Sydney, Australia) 
device was used to examine arterial stiffness. 
Carotid-femoral pulse wave velocity (PWV) and 
central blood pressure in the aorta were measured 
according to ESC expert consensus recommenda-
tions [17, 18]. Echocardiographic examination us-
ing the Vivid 7® VingMed (GE-Healthcare Chicago, 
IL, USA) device was performed in accordance 
with the ESH/ESC guidelines for the management 
of hypertension [16]. The left ventricular mass 
(LVM) was calculated according to the Devereaux 
formula using the Penn convention LVM = 1.04 
([left ventricular internal diameter in diastole + 
posterior wall thickness in diastole + interven-
tricular septum thickness in diastole]3 – [left 
ventricular internal diameter in diastole]3) – 13.6 g 
[19]. Ultrasound carotid arteries were examined 
with intima–media thickness (IMT) measurement 
of common carotid artery and was carried out in ac-
cordance with recommendations of the Mannheim 
consensus with the use of the Vivid 7® VingMed 
(GE-Healthcare Chicago, IL, USA) [20]. 
Measurements of serum concentrations of 
UA, creatinine, total cholesterol, high-density 
lipoprotein cholesterol (HDL-C), low-density lipo-
protein cholesterol (LDL-C) and triglycerides were 
performed. Blood samples from the antecubital 
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vein were taken for the determination of serum 
concentrations of metalloproteinases (MMP-1, 
MMP-2, MMP-3 and MMP-9) and tissue inhibitor 
of matrix metalloproteinases-1 (TIMP-1) in the 
morning hours before study procedures. Then the 
plasma was separated and samples stored at –75°C 
until analysis. TIMP-1 plasma concentrations were 
measured using an ELISA kit (Human TIMP-1 
Immunoassay, Quantikine, R&D Systems Europe, 
Ltd. Abingdon, UK). The concentration of serum 
metalloproteinases was measured using kits from 
R&D Systems Europe Ltd, Abingdon, UK. 
According to The Third National Health and 
Nutrition Examination Survey (NHANES III, 
1988–1994) hyperuricemia was defined as UA 
concentration > 7 mg/dL (416 μmol/L) in men and 
> 5.7 mg/dL (339 μmol/L) in women [21]. Based 
on the cut-off values, the study group was divided 
into hyper- and normuricemia group.
Statistical analysis
Statistical analyses were performed with STA-
TISTICA software (StatSoft, Poland), version 13.1. 
Nonparametric tests were used, because some of the 
variables studied did not have a normal distribution 
and study subgroups had different numbers. Groups 
were compared using the Mann-Witney U test and 
the association between variables was studied using 
the Spearman rank correlation. For the evaluation 
of association of HMOD with UA concentration, 
multivariate regression analysis was used. P-values 
< 0.05 were considered statistically significant.
Results
Relation of UA serum concentration with 
the hypertension-mediated organ damage 
and selected biochemical parameters
The body mass index (BMI) was 27.4 (24.3; 
30.1) kg/m2, office systolic blood pressure (SBP-
office) was 150 (135; 162) mmHg, office dias-
tolic blood pressure (DBP-office) was 93 (86; 100) 
mmHg, heart rate (HR) was 72 (66;79) bpm, cre-
atinine was 65.9 (58.2; 74) μmol/L, PWV was 7.8 
(7.1; 9.1) m/s, IMT was 0.6 (0.55; 0.75) mm, left 
ventricular mass index (LVMI) was 132.2 (103.9; 
144) g. UA concentration in the whole study group 
positively correlated with: BMI, waist circumfer-
ence, BP and some HMOD parameters (IMT, PWV, 
LVMI, left atrial dimension) and triglyceride level. 
UA concentration in the study group negatively 
correlated with HDL-C level. Among the metal-
loproteinases studied, only MMP-3 activity was 
positively correlated with UA serum concentration 
(Fig. 1, Table 1). In multivariate regression analy-
sis, after adjustment for age, BMI and serum lipids, 
UA associated with higher MMP-3 activity (R2 = 
= 0.11, beta = 0.332, p = 0.048) (Fig. 2) and PWV 
(R2 = 0.33, beta = 0.230, p = 0.0004), thicker IMT 
(R2 = 0.34, beta = 0.240, p = 0.04) and increased 
LVMI (R2 = 0.11, beta = 0.232, p = 0.0004). 
The activity of MMP-3 correlated, like the 
concentration of UA, with the IMT (r = 0.292; 
p = 0.002) and the LVMI (r = 0.273; p = 0.009).
In further analyses, both factors, MMP-3 and 
UA serum activity together with waist circumfer-
ence, SBP and DBP obtained in 24-h ABPM and 
serum lipids into the multivariate regression model 
were used to evaluate their influence on selected 
parameters of HMOD.  
IMT value in this model was significantly posi-
tively associated with SBP and DBP (24-h mean 
values in ABPM), UA serum concentration and 
MMP-3 activity (R2 = 0.328, p < 0.002).  
Only the SBP and DBP were significant deter-
minants of PWV (R2 = 0.25, p = 0.0047).
The same multivariate regression model was 
not sufficient to explain LVMI variability in the 
group (p > 0.05).
Differences in clinical profiles of hyperten-
sives with normo- or hyperuricemia
The hyperuricemic group consisted of 21 
subjects (15 women, 6 men). The group with nor-
mouricaemia consisted of 88 subjects (40 women, 
48 men).
Hypertensive patients with HU were charac-
terized by higher BMI and waist circumference in 
comparison to patients without HU (Table 2).
In the HU group, higher SBP during daily ac-
tivity and higher SBP and DBP during night-time 
were observed than in the normouricemic group 
(Table 2).
The group with HU compared to the normour-
icemic group had lower HDL-C values and higher 
triglyceride serum concentrations (Table 3). 
Between-group differences in activity of se-
lected MMPs (-1, -2, -3 and -9) and TIMP-1 were 
analyzed. Only for MMP-3 activity was a statisti-
cally significant difference obtained. Patients with 
HU were characterized by higher activity of MMP-3 
in relation to patients without HU (Table 3).
There were no significant differences in the 
prevalence of diabetes or pre-diabetic conditions 
between the group with HU and the normouricamic 
group.
The comparison of HMOD parameters be-
tween the present groups showed a greater IMT 
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of the common carotid artery and larger left atrium 
dimension in the M-mode parasternal long axis 
view in the hyperuricemic group. Patients with HU 
were also characterized by higher LVM, however, 
this difference lost significance after indexing the 
body surface (LVMI). There were no significant dif-
ferences between the groups examined in carotid-
femoral pulse wave velocity (Table 4).
Discussion
The relationship between elevated serum UA 
level and arterial BP is well documented in the 
literature. The analysis of the Framingham Study 
population showed positive correlations between 
SBP and DBP and UA [22]. The current study also 
observed a positive correlation of UA concentration 
with systolic and diastolic office BP values. A new 
result in the present study was a higher BP at night 
in patients with HU compared to normouricemic 
patients. 
Elevated UA serum level is often recognized 
as an integral component of metabolic syndrome 
[23, 24]. The metabolic syndrome, as defined by the 
International Diabetes Federation in 2006, consists 
of: increased triglycerides and reduced HDL-C serum 
level, arterial hypertension, raised fasting plasma 
glucose or previously diagnosed type 2 diabetes and 
of course abdominal obesity [25]. The results the 
study herein, showed a positive correlation of most 
components of the metabolic syndrome with UA 
serum concentration. The hyperuricemic group was 
also characterized by: higher BMI, waist circumfer-
ence, triglyceride concentration and lower serum 
HDL-C level. However, differences in the frequency 
of diabetes and pre-diabetes between normouricemic 
and hyperuricemic group were not observed.
The biochemical characteristics of the group 
with HU and essential hypertension in the current 
study was completed by higher MMP-3 activity 
in comparison to patients without HU. MMP-3, 
is a proteolytic enzyme playing a main role in the 
Figure 1. The relationship between selected matrix metalloproteinase (MMP-1, -2, -3, and -9) and uric acid (UA) 
concentration.
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activation  of other MMPs. The cascade of MMPs 
is responsible for the degradation of collagen and 
other fibrile proteins, leading to the remodeling 
of vascular wall, formation and destabilization of 
atherosclerotic plaque [26, 27]. 
In many diseases, MMPs are over-expressed 
and their over-activity leads to pathological heart 
and vessel remodeling, and the development of 
cardiovascular diseases [7, 28]. Increased activity 
of MMP-1, -2, -3 and -9 might also be associated 
with a higher risk of death independently of other 
typical cardiovascular risk factors [29]. 
The most important result of the present 
study is a strong, independent association between 
increased activity of MMP-3 UA serum concentra-
tion in patients with mild to moderate essential 
arterial hypertension. The data about the associa-
tion of MMP-3 activity and UA concentration in the 
literature is limited and includes subjects with in-
flammatory diseases. Increased activity of MMP-3 
has been reported in gout and acute arthritis [30, 
31]. In patients with lupus erythematosus a positive 
correlation of plasma MMP-3 and UA concentration 
was observed. The latter is similar to present results 
obtained in patients with essential arterial hyperten-
sion free of acute or chronic inflammatory diseases 
[32]. A positive relationship between plasma activity 
of collagenase-2 (MMP-2) and UA concentration 
in men with coronary artery disease was reported 
[33, 34]. Tan et al. [35] showed that higher activity 
of MMP-9 coexists with higher concentrations of 
UA and higher IMT. In opposition to the above-
mentioned results in an experimental animal study 
performed in rats showed that UA-induced inflam-
mation led to a decrease in MMP-9 activity [36]. 
Similarly, UA administration during acute phase of 
ischemic stroke decreased the activity of proinflam-
matory MMP-9 [37]. In the present study MMP-2 
and MMP-9 activity did not show a significant as-
sociation with UA level or HMOD parameters.
Figure 2. Association between matrix metalloproteinase 3 
(MMP-3) and uric acid (UA) serum levels after adjust-
ment to: age, waist circumference, total cholesterol, low 
density lipoprotein cholesterol, high density lipoprotein 
cholesterol and triglycerides serum concentration. Uric 
acid = 0.278 × MMP-3 + 259.9.
Table 1. The correlations of serum uric acid (UA) 
concentration with selected variables.
Selected variable Correlation 
 coefficient (r) 
with UA
P
BMI 0.376 < 0.001
Waist circumference 0.486 < 0.001
SBP office 0.104 0.308
DBP office 0.223 0.027
24-h SBP 0.247 0.025
24-h DBP 0.238 0.032
SBP day 0.189 0.051
DBP day 0.256 0.008
SBP night 0.259 0.008
DBP night 0.264 0.007
Central BP 0.235 0.016
IMT 0.241 0.012
PWV 0.203 0.037
Alx-c –0.237 0.015
HDL-C –0.261 0.006
Triglycerides 0.362 < 0.001
Creatinine 0.339 < 0.001
MMP-1 0.053 0.590
MMP-2 –0.18 0.063
MMP-3 0.339 < 0.001
MMP-9 –0.003 0.972
TIMP 0.051 0.605
LVMI 0.197 0.040
LVM 0.376 < 0.001
LA (PLAX) 0.487 < 0.001
BMI — body mass index; SBP office — office systolic blood pres-
sure; DBP office — office diastolic blood pressure; 24-h SBP — 24-
hour systolic blood pressure; 24-h DBP — 24-hour diastolic blood 
pressure; SBP night — systolic nighttime blood pressure; DBP 
night — diastolic nighttime blood pressure; SBP day — systolic 
blood pressure during daily activity; DBP day — diastolic blood 
pressure during daily activity; BP — blood pressure; ITM — in-
tima–media thickness; PWV — pulse wave velocity; Alx-c — central 
augmentation index; HDL-C — high density lipoprotein cholesterol; 
MMP-1, -2, -3, -9 — matrix metalloproteinase 1, 2, 3, 9; TIMP — tis-
sue inhibitor of metalloproteinases; LVMI — left ventricular mass 
index; LVM — left ventricular mass, LA — left atrium dimension in 
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Lien et al. [38] studied various plasma met-
alloproteinase activity in atherosclerosis. Only 
increased MMP-3 activity showed a significant 
relationship with the degree of atherosclerosis in 
the carotid arteries. A similar result was obtained 
in our study. The severity of atherosclerosis in 
carotid arteries evaluated by IMT was related to 
UA and MMP-3 concentrations. Kawamoto et al. 
[39] showed that UA in men may increase carotid 
atherosclerosis independent of other factors. The 
authors concluded that people with hypertension 
and hyperuricemia are characterized by greater IMT 
than hypertensive patients without HU. Increased 
IMT in this study correlated with UA concentration 
independently of the BP level. Hyperuricemia may 
also negatively affect other HMOD indicators [40]. 
In a population of more than 4,000 healthy par-
ticipants selected from the Generation 3 Framing-
Table 2. Groups characteristics. Anthropometric and clinical data.
Selected variable Hyperuricemic group  
(n = 21)
Normouricemic group 
(n = 88)
P  
(the Mann-Whitney U test)
Age [years] 52 (43; 60) 54 (42; 61) 0.030
Sex (no. of females) 15 (71.4%) 40 (45.5%) 0.803
Weight [kg] 88 (84; 95) 75 (65; 86) < 0.001
Haight [cm] 172 (170; 176) 169 (162; 176) 0.1477
BMI [kg/m2] 30.08 (28.4; 33.53) 26.8 (23.85; 29;48) < 0.001
Waist circumference [cm] 99 (92;106) 90 (81; 97) < 0.001
Heart rate [bpm] 70 (64; 75) 72 (67; 80) 0.203
SBP office [mmHg] 155 (140; 178) 150 (135; 161) 0.176
DBP office [mmHg] 94 (90; 109) 92 (85; 99) 0.073
24h SBP [mmHg] 134 (123; 138) 128 (120; 132) 0.070
24h DBP [mmHg] 82 (76; 87) 77 (72; 84) 0.118
SBP day [mmHg] 136 (125; 140) 126 (119; 133) 0.015
DBP day [mmHg] 83 (77; 89) 80 (74; 85) 0.092
SBP night [mmHg] 119 (112; 129) 114 (107; 121) 0.016
DBP night [mmHg] 73 (67; 77) 68 (62; 73) 0.022
Values presented as medians (interquartiles ranges) or numbers (part of the group in %). Abbreviations — see Table 1.
Table 3. Group characteristics. Biochemical blood tests.
Selected variable Hyperuricemic group  
(n = 21)
Normouricemic group 
(n = 88)
P  
(the Mann-Whitney U test)
Uric acid [µmol/L] 449 (416; 487) 268 (235; 324) < 0.001
MMP-1 [ng/mL] 3.51 (2.13; 8.64) 3.43 (1.99; 5.76) 0.350
MMP-2 [ng/mL] 203.8 (186.2; 218.8) 214.7 (189; 239.4) 0.233
MMP-3 [ng/mL] 19.41 (14.45; 21.74) 13.98 (9.52; 18.97) 0.016
MMP-9 [ng/mL] 350.1 (245.1; 432.3) 335.6 (209.9; 442.9) 0.417
TIMP [ng/mL] 92.9 (81.2; 106.8) 86.8 (80; 101.3) 0.335
Creatinine [µmol/L] 68.9 (64.2; 78.9) 65.15 (57.65; 72.55) 0.027
Urea [mmol/L] 6.1 (5.2; 6.8) 5.5 (4.55; 6.3) 0.0739
Total cholesterol [mmol/L] 5.43 (4.87; 5.99) 5.27 (4.57; 6.08) 0.563
LDL-C [mmol/L] 3 (2.71; 3.86) 3.21 (2.44; 3.75) 0.482
HDL-C [mmol/L] 1.17 (1.09; 1.5) 1.44 (1.19; 1.7) 0.029
Triglycerides [mmol/L] 1.56 (1.16; 2.18) 1.2 (0.94; 1.57) 0.018
Values presented as medians (interquartiles ranges). LDL-C — low density lipoprotein cholesterol; other abbreviations — see Table 1.
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ham cohort, an independent positive relationship 
between UA level and carotid-femoral PWV was 
proved [41]. In a much smaller study, carried out 
with a group of 222 subjects with essential hyper-
tension, a positive correlation of PWV with UA in 
hypertensive patients was also observed [42]. In 
the current study, the group of patients with es-
sential hypertension showed a positive correlation 
of arterial stiffness (evaluated by carotid-femoral 
PWV) with UA concentration.
There are existing reports in the literature 
indicating that UA serum concentration is associ-
ated with decreased left ventricular function and 
left ventricle hypertrophy [43, 44]. In the patients 
of this study a positive correlation was observed 
between UA and LVMI and UA and the left atrium 
dimension. Similar results have been described by 
Tavil et al. [45]. The current study also performed 
a multivariate regression analysis of the simul-
taneous effect of UA and MMP-3 concentrations 
on the other HMODs. Analysis for LVMI did not 
show statistical significance. In the case of PWV, 
BP values played the main role, and the effects of 
UA and MMP-3 were not significant.
Based on these results and data from the litera-
ture, it was suspected that among different indica-
tors of HMOD (except for) hypertension there are 
big differences in factors determining their devel-
opment and advancement. IMT is the HMOD most 
closely reflecting atherosclerosis; in the present 
study it was associated with proinflammatory factors 
like UA concentration and MMP-3 activity. Results 
obtained herein may support the thesis that UA and 
increased by UA activity of MMPs may take part in 
the development of HMOD, especially IMT. These 
results are consistent with the inflammatory and 
free radicals hypothesis of UA side effects.
However UA may play both pro- and anti-
oxidative roles, depending on its concentration, 
solubility and place of action (plasma or cells) [46], 
free radicals formed in various mechanisms in hy-
peruricemia [47] have a great potential to activate 
various inflammatory mechanisms, including the 
activation of metalloproteinases cascade [48]. 
Conclusions
In patients with primary arterial hypertension 
UA concentration is associated with higher MMP-3 
serum activity and selected hypertension-mediated 
organ damage advancement, especially carotid 
IMT. Patients with HU and arterial hypertension 
are characterized by a symptom cluster typical for 
metabolic syndrome and more advanced structural 
changes in the heart and vessels as well as higher 
activity of MMP-3.
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